Use of Digital Twins in a Phase 2a Trial to Predict Disease-Progression of Participants with Mild-to-Moderate Alzheimer's Disease Supports Early Signals of Efficacy

"Digital twins offer a new lens for interpreting biomarker trends over time, especially in early-stage trials where every data point matters." Gerard Griffioen, Ph.D., CSO, reMYND. Presented at AD/PD 2025, Boston, MA.